Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | ATM | Q13315 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.42 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.42 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | IKBKB | O14920 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | MMP3 | P08254 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | METAP2 | P50579 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5745546 | 0.84 | KDM4E (0.64) | KDM4EALDH1A1GAAKMT2AATM | |
| SCHEMBL5966238 | 0.82 | NR4A1 (0.59) | KDM4EALDH1A1KMT2APOLBNR4A1 | |
| SCHEMBL5745519 | 0.78 | KDM4E (0.51) | KDM4EALDH1A1GAAKMT2AATM | |
| Water SCHEMBL3981101 | 0.78 | KDM4E (0.66) | KDM4EALDH1A1GAAKMT2AATM | |
| SCHEMBL16289430 | 0.77 | KDM4E (0.50) | KDM4EALDH1A1KMT2AATMPOLB | |
| SCHEMBL43084 | 0.75 | KDM4E (0.68) | KDM4EALDH1A1GAAKMT2AATM | |
| SCHEMBL29381201 | 0.75 | KDM4E (0.68) | KDM4EALDH1A1GAAKMT2AATM | |
| SCHEMBL294090 | 0.75 | LMNA (0.47) | KDM4EALDH1A1KMT2APOLBSMN1; SMN2 | |
| SCHEMBL9011545 | 0.74 | KDM4E (0.66) | KDM4EALDH1A1GAAKMT2AATM | |
| SCHEMBL18859030 | 0.74 | KDM4E (0.66) | KDM4EALDH1A1GAAKMT2AATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025064469-A1 | METHODS FOR ASSESSING DOSAGE FOR EPIGENETIC MODIFYING AGENTS | OMEGA THERAPEUTICS, INC. (US) | 2025-03-27 | — | — | WO | disclosed |
| EP-4482488-A1 | A CATIONIC DENDRIMER FOR IMPROVING ANTIBIOTIC EFFICACY OF AN ANTIBIOTIC | GAMA HEALTHCARE LTD (GB) | 2025-01-01 | — | — | EP | disclosed |
| US-12102634-B2 | Use of berbamine or its analogue for preventing or treating RNA virus infection | 6J BIOTECHNOLOGY (HONG KONG) LIMITED (HK) | 2024-10-01 | — | — | US | disclosed |
| WO-2023161361-A1 | A CATIONIC DENDRIMER FOR IMPROVING ANTIBIOTIC EFFICACY OF AN ANTIBIOTIC | GAMA HEALTHCARE LTD (GB) | 2023-08-31 | — | — | WO | disclosed |
| US-20220378778-A1 | Use of Berbamine or its Analogue for Preventing or Treating RNA Virus Infection | CITY UNIVERSITY OF HONG KONG (HK) | 2022-12-01 | — | — | US | disclosed |
| EP-1809332-A2 | COMPOSITIONS FOR MULTI-STEP DELIVERY OF HOT-SPOTS RADIATION TO CANCER CELLS | Oncologic, Inc. (US) | 2007-07-25 | — | — | EP | disclosed |
| US-20060293503-A1 | Polyaminopyridines and method for producing same | SUMITOMO SEIKA CHEMICALS CO., LTD (JP) | 2006-12-28 | — | — | US | disclosed |
| EP-1669390-A1 | POLYAMINOPYRIDINES AND METHOD FOR PRODUCING SAME | SUMITOMO SEIKA CHEMICALS CO., LTD. (JP) | 2006-06-14 | — | — | EP | disclosed |
| WO-2006010165-A2 | COMPOSITIONS FOR MULTI-STEP DELIVERY OF HOT-SPOTS RADIATION TO CANCER CELLS | ONCOLOGIC, INC. (US) | 2006-01-26 | — | — | WO | disclosed |
| EP-0820283-A4 | LACTACYSTIN ANALOGS | HARVARD COLLEGE (US) | 1998-07-08 | — | — | EP | disclosed |
| EP-0823942-A1 | EFFLUX PUMP INHIBITORS | Microcide Pharmaceuticals, Inc. (US) | 1998-02-18 | — | — | EP | disclosed |
| EP-0820283-A1 | LACTACYSTIN ANALOGS | THE PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 1998-01-28 | — | — | EP | disclosed |
| WO-1996033285-A1 | EFFLUX PUMP INHIBITORS | MICROCIDE PHARMACEUTICALS, INC. (US) | 1996-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220378778-A1 | Use of Berbamine or its Analogue for Preventing or Treating RNA Virus Infection | SARS1, ACE2, ACE | KDM4E 1331/4885ALDH1A1 1848/4885GAA 2930/4885 |
| US-12102634-B2 | Use of berbamine or its analogue for preventing or treating RNA virus infection | SARS1, ACE2, ZC3HAV1 | KDM4E 1501/4885ALDH1A1 1617/4885GAA 2439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.